What Protein Does Pembrolizumab Bind?
Pembrolizumab, sold as Keytruda, directly binds to PD-1 (programmed cell death protein 1), a receptor on T cells.[1]
How Does This Binding Work?
PD-1 normally interacts with PD-L1 or PD-L2 on tumor cells, inhibiting T-cell activity and allowing immune evasion. Pembrolizumab blocks PD-1, preventing this interaction and reactivating T cells to attack cancer.[1][2]
Why Target PD-1 Specifically?
PD-1 is an immune checkpoint overexpressed in many cancers. Drugs like pembrolizumab restore anti-tumor immunity without broadly suppressing the immune system.[2]
Comparison with Nivolumab or Other PD-1 Inhibitors
Pembrolizumab and nivolumab both target PD-1 but differ in structure and half-life. Nivolumab (Opdivo) has a similar mechanism but binds with higher affinity; clinical outcomes are comparable in trials for melanoma and lung cancer.[2][3]
Does It Bind PD-L1 Instead?
No, pembrolizumab is anti-PD-1. PD-L1 inhibitors like atezolizumab bind the ligand on tumor cells, achieving similar checkpoint blockade via a different pathway.[2]
Clinical Approvals Tied to PD-1 Binding
FDA approved pembrolizumab in 2014 for melanoma based on PD-1 inhibition data; expanded to over 30 indications including NSCLC and head/neck cancers.[1]
[1]: FDA Label for Keytruda
[2]: Nature Reviews Drug Discovery - PD-1/PD-L1 Inhibitors
[3]: DrugPatentWatch.com - Pembrolizumab Patents